Packaging Line Clearance: Lessons From a 2026 Kit Recall

On 30 July 2026, Health Canada posted a recall for Femyso, a mifepristone and misoprostol tablets kit distributed by Lupin Pharma Canada Limited. The reason was unusual. The tablets were fine. Both drugs met their specifications. What failed was the box. Affected lots could contain two green mifepristone cartons or two pink misoprostol cartons instead of one of each.

A patient could open a sealed, complete-looking kit and find a duplicate of one medicine and none of the other. There is no adverse reaction to trace and no impurity to test for. The harm is the quiet absence of a required component. This is a packaging line failure, not a formulation failure, and it lands squarely on the part of your quality system that is most often treated as an afterthought. This article explains what line clearance, segregation and reconciliation should have caught, and how to build packaging controls that hold up when an inspector asks about them.

Executive Summary

Packaging is where a good product becomes a recall. The Femyso kit was colour coded green and pink precisely so the two cartons could not be confused, and the wrong pair still went into the box. That tells you something important: colour differentiation is a design control, and design controls do not replace the process controls that catch human and equipment error on the line.

The controls that should have caught a same-count, wrong-composition kit are line clearance between kit configurations, physical segregation of components, and a reconciliation that counts cartons in against kits out. A simple unit count would not have flagged this defect, because the total number of items in the box was correct. Every packaging operation in pharmaceuticals, natural health products, medical devices and cannabis should be able to answer the five control questions set out below.

What Happened: The Femyso Kit Recall

What it is. Femyso is a combination kit containing mifepristone tablets and misoprostol tablets, used together in a defined sequence. On 30 July 2026, Health Canada published a recall because affected lots may contain two green mifepristone cartons or two pink misoprostol cartons instead of one of each carton.

Why it matters. The individual drug products were not defective. The failure occurred at secondary packaging, where two visually distinct cartons are combined into a single outer kit and the wrong pair was assembled into the box. A patient receives a kit that looks complete but cannot be used as directed because one component is missing and the other is duplicated.

What to do. Treat kit and combination-product assembly as a distinct, high-risk packaging operation. Verify that your line clearance, component segregation and reconciliation steps are designed to detect a wrong-composition assembly, not just a wrong count. If you package combination kits under contract, confirm that your contract packager can demonstrate the same.

The primary record sits in the Health Canada Recalls and Safety Alerts database. The lesson, however, applies to any operation that assembles more than one component into a single saleable unit.

Why a Colour-Coded Kit Still Failed

What it is. Colour coding, distinct carton shapes and printed differentiation are design controls. They make an error easier for a person to notice, but they depend on a person noticing.

Why it matters. The Femyso cartons were deliberately green and pink so they could not be confused. The error happened anyway. That is the whole point. When an operation relies on operator vigilance and visual cues rather than on an engineered or documented control, a lapse becomes a shipped defect. Design controls reduce the probability of error; process controls are what catch the error when it occurs.

What to do. Map every packaging step and classify each control as either a design control or a process control. Where a step depends on someone seeing the difference, add a process control that does not: physical segregation, a verified in-process check, a vision system, or a reconciliation that makes an undetected error mathematically visible.

What Line Clearance Actually Requires

The Femyso failure is a line clearance and changeover problem as much as an assembly problem. When a line switches between kit configurations, or between the components that go into a kit, the risk is that material from the previous setup remains in a feed station, a hopper or a staging area. If a station still holds green cartons when it should hold pink, the wrong pair enters the box without any single operator making an obvious mistake.

Effective line clearance for kit assembly goes beyond a generic checklist. It confirms that each feed position holds the correct component for the current configuration, that no component from the previous run remains anywhere on the line, and that the batch packaging record names the configuration being run so the clearance can be verified against it. A clearance that only asks whether the line looks clean is not enough for a multi-component kit.

Packaging Reconciliation: Why a Unit Count Would Not Have Caught This

What it is. Reconciliation is the accounting step that compares the quantity of components issued to the line with the number of finished units produced, plus rejects, samples and waste. Discrepancies must be investigated and explained before the batch is released.

Why it matters. A defect like the Femyso kit is invisible to a simple unit count. If the box should hold two cartons and it holds two cartons, the count is correct even when the composition is wrong. To detect a two-of-one-and-none-of-the-other error, reconciliation has to be done per component, not per unit. You reconcile green cartons issued against green cartons packed, and pink against pink, so that an imbalance surfaces on paper even if no one saw it on the line.

What to do. Design reconciliation at the component level for every kit or combination product. Set investigation limits, require a documented explanation for any significant or unusual discrepancy, and make component reconciliation a release gate rather than a formality signed after the fact.

EU GMP requires that any significant or unusual discrepancy observed during reconciliation be investigated and satisfactorily accounted for before release (EudraLex Volume 4, Chapter 5). A per-component reconciliation is the practical expression of that requirement for kits.

The Five Control Questions Every Packaging Operation Should Answer

Use these five questions to challenge your own line against the Femyso scenario. If you cannot answer all five with a documented yes, you have a gap.

• Is line clearance documented between kit configurations, not only between different products?
• Is there a component reconciliation at kit assembly, counting cartons in against kits out, per component?
• Is there an in-process check, by weight, vision system or verified manual check, capable of detecting a same-count, wrong-composition kit?
• Are packaging components physically segregated, or does the line rely on operator vigilance and colour?
• Does the batch packaging record capture the challenge and the result for each check, or only the final sign-off?

The Canadian Requirements: FDR Part C Division 2, C.02.016 and GUI-0001

What it is. In Canada, good manufacturing practices for drugs are set out in the Food and Drug Regulations, Part C, Division 2, and interpreted in Health Canada's GUI-0001. Packaging is treated as an integral GMP activity, not a downstream add-on.

Why it matters. Section C.02.016 addresses the testing of packaging materials. Health Canada's rationale is direct: drug quality is directly dependent upon packaging quality. Line clearance, segregation and reconciliation are the operational controls that keep packaging quality from becoming a product-quality problem, and they are exactly what an inspector will probe after a packaging recall.

What to do. Confirm that your packaging material controls, batch packaging records and standard operating procedures reflect the expectations in GUI-0001. Records should show that clearance and reconciliation were performed and reviewed, that components were released against specification, and that any deviation was investigated and closed.

The interpretive guidance is Health Canada's Good manufacturing practices guide for drug products (GUI-0001).

The underlying legal requirements are in the Food and Drug Regulations, Part C, Division 2 on the Justice Laws website.

EU and International Expectations: EudraLex Chapter 5

What it is. EU GMP addresses packaging operations, line clearance and reconciliation in EudraLex Volume 4, Chapter 5 (Production). Any Canadian site exporting to the EU, or holding EU-GMP certification, is assessed against these expectations.

Why it matters. Chapter 5 expects checks before packaging begins to confirm the line and equipment are clear of previous products and materials, and it requires that discrepancies found during reconciliation be investigated and satisfactorily accounted for before release. The principles are consistent with Canadian GMP, so a control system built to satisfy one will generally satisfy the other, which matters for exporters running a single quality system across markets.

What to do. If you package for multiple markets, align your line clearance and reconciliation procedures to the stricter of the applicable expectations and document them once. Confirm paragraph references against the current European Commission text, since Chapter 5 numbering has shifted across revisions.

Common Inspection Findings in Packaging Operations

Packaging is a recurring source of GMP observations. In our audit and gap-assessment work, the findings that surface most often are practical and avoidable:

• Line clearance recorded as a tick box, with no evidence of what was actually checked or removed.
• Reconciliation performed at the unit level only, so a wrong-composition or wrong-label error cannot be detected on paper.
• No defined line clearance between configurations of the same product, only between different products.
• Components staged on or near the line without physical segregation, relying on colour or operator memory.
• In-process checks signed at the end of the run rather than at the point and time they were performed.
• Contract packagers operating to their own procedures with no evidence the sponsor reviewed or approved them.

When one of these becomes a deviation, the investigation quality decides the outcome. A weak root-cause analysis invites a repeat. Our guide on why CAPA keeps failing explains how to build corrective actions that survive the next inspection.

Packaging Line Control Compliance Checklist

Work through this checklist for each packaging line and each kit or combination product it runs:

• Line clearance procedure defines checks between products and between configurations of the same product.
• Line clearance record captures what was checked, what was removed and who verified it.
• Batch packaging record names the exact configuration being run and links to the approved specification.
• Components are physically segregated at staging and at each feed position.
• Component reconciliation is performed per component, not per finished unit.
• Investigation limits are defined and any significant or unusual discrepancy is investigated before release.
• An in-process check can detect a same-count, wrong-composition unit (weight, vision or verified manual check).
• In-process checks are recorded at the time and point of performance, with challenge and result.
• Packaging materials are tested and released against specification per C.02.016 and GUI-0001.
• Contract packager procedures are reviewed and approved, with a current quality agreement in place.
• Deviations feed a root-cause investigation and effective CAPA, not just a re-check.
• A mock recall confirms you can identify and retrieve every affected kit by lot.

Common Mistakes to Avoid

Treating colour coding as a control. Visual differentiation lowers risk but does not detect error. Pair every visual cue with a process control that works even when no one is looking.

Reconciling only finished units. Unit-level reconciliation cannot see a wrong-composition kit. Reconcile each component separately so an imbalance appears on paper.

Clearing only between products. Most mix-ups on multi-component lines happen at configuration changeovers within the same product. Line clearance must cover those too.

Signing checks after the run. A check recorded at the end of the batch is not evidence the check happened when it mattered. Record at the point of performance.

Assuming the contract packager has it covered. Sponsors remain accountable. Review and approve packaging procedures and hold a current quality agreement.

Frequently Asked Questions

What is line clearance in pharmaceutical packaging?

Line clearance is the documented check performed before a packaging run begins, confirming that the line, equipment and work area are clear of all products, components, labels and documents from the previous job. It prevents mix-ups between batches and between configurations of the same product, and it is a core GMP expectation under both Health Canada's GUI-0001 and EU GMP Chapter 5.

What is packaging reconciliation and why does it matter?

Reconciliation compares the quantity of components issued to the line with the number of finished units produced, plus rejects, samples and waste. Any significant or unusual discrepancy must be investigated and explained before the batch is released. For kits and combination products, reconciliation must be done per component, because a unit count alone cannot detect a box that holds the right number of items in the wrong combination.

Why was Femyso recalled in Canada?

Health Canada posted the recall on 30 July 2026 because affected lots of the Femyso kit could contain two green mifepristone cartons or two pink misoprostol cartons instead of one of each. The tablets themselves met specification. The defect occurred during secondary packaging and kit assembly, making it a packaging control failure rather than a product-quality failure.

How could a colour-coded kit still be packed wrong?

Colour coding is a design control. It makes an error easier for a person to notice, but it relies on that person noticing. When a control depends on operator vigilance rather than on segregation, a verified check or a reconciliation, a lapse becomes a shipped defect. Robust operations back every visual cue with a process control that catches the error regardless of attention.

Which Canadian regulations govern drug packaging quality?

Packaging is governed by the Food and Drug Regulations, Part C, Division 2, with interpretive guidance in Health Canada's GUI-0001. Section C.02.016 addresses packaging material testing, on the principle that drug quality is directly dependent upon packaging quality. Line clearance, segregation and reconciliation are the operational controls that keep packaging quality from becoming a product-quality problem.

Do these controls apply to NHP, medical device and cannabis packaging?

Yes. The same failure mode, a same-count but wrong-composition or wrong-label unit, can occur in any operation that assembles components into a saleable unit. Natural health products, medical devices and cannabis products all package multiple components, kits or multi-pack formats, and all are subject to line clearance and reconciliation expectations under their respective frameworks.

How MFLRC Can Help

MF License and Regulatory Consultants helps manufacturers, importers and contract packagers build packaging controls that hold up under inspection and prevent the kind of failure behind the Femyso recall. Our work is practical and grounded in what inspectors actually examine after a packaging deviation.

• Packaging operations gap assessment, challenging your line clearance, segregation and reconciliation against wrong-composition and wrong-label scenarios.
• SOP development and batch packaging record design, so clearance and reconciliation are captured at the point of performance.
• Pharmaceutical validation services, including packaging validation and validation master planning.
• CAPA and investigation support that produces defensible root-cause analysis, not repeat findings.
• Mock recall and recall-readiness exercises to confirm you can retrieve every affected unit by lot.

Explore our pharmaceutical validation services and

our quality control services, or see how we structure a validation programme in our guide to the

validation master plan.

Conclusion

The Femyso recall is a clean lesson in the difference between design controls and process controls. Two cartons were coloured green and pink so they could never be confused, and the wrong pair was still packed into the box. Colour coding did its job as a design control and it was not enough, because nothing on the line was engineered or documented to catch the error once it occurred.

Line clearance between configurations, physical segregation of components, an in-process check that can see a wrong-composition unit, and reconciliation done per component are what close that gap. Build them into your procedures and your batch packaging record, challenge them against a realistic failure scenario, and confirm your contract packagers do the same. That is the difference between a controlled operation and a recall waiting to happen.

Sources and References

Health Canada, Recalls and Safety Alerts database

Health Canada, Good manufacturing practices guide for drug products (GUI-0001)

Food and Drug Regulations, Part C, Division 2 (Justice Laws Canada)

European Commission, EudraLex Volume 4, Chapter 5: Production

Health Canada, Guide for recalling medical devices (GUI-0054)